Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 16,569 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 16,569 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the sale, the chief executive officer owned 708,719 shares in the company, valued at approximately $48,844,913.48. This trade represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Helen Torley also recently made the following trade(s):

• On Tuesday, November 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.13, for a total value of $1,382,600.00.
• On Wednesday, October 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00.
• On Friday, October 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.03, for a total value of $1,380,600.00.
• On Wednesday, September 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $74.44, for a total transaction of $1,488,800.00.

Halozyme Therapeutics Stock Performance

HALO traded down $3.30 during trading on Monday, reaching $68.10. The company’s stock had a trading volume of 2,269,023 shares, compared to its average volume of 2,031,001. Halozyme Therapeutics, Inc. has a 52-week low of $46.26 and a 52-week high of $79.50. The company’s fifty day moving average price is $69.25 and its 200-day moving average price is $63.96. The company has a market capitalization of $8.01 billion, a price-to-earnings ratio of 15.58, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. During the same period in the prior year, the business posted $1.27 EPS. The company’s revenue for the quarter was up 22.1% on a year-over-year basis. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Zacks Research lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. The Goldman Sachs Group boosted their price target on Halozyme Therapeutics from $54.00 to $56.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 18th. Finally, JMP Securities upped their price target on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. Seven equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $75.10.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in HALO. Redhawk Wealth Advisors Inc. grew its holdings in Halozyme Therapeutics by 14.8% during the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock worth $1,947,000 after acquiring an additional 4,827 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Halozyme Therapeutics by 9.9% during the first quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock worth $9,776,000 after purchasing an additional 13,789 shares during the last quarter. Focus Partners Wealth lifted its position in shares of Halozyme Therapeutics by 57.8% during the first quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company’s stock worth $7,709,000 after purchasing an additional 44,260 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its stake in Halozyme Therapeutics by 78.0% in the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 102,000 shares of the biopharmaceutical company’s stock worth $5,305,000 after purchasing an additional 44,700 shares in the last quarter. Finally, Shelton Wealth Management LLC bought a new stake in Halozyme Therapeutics in the second quarter valued at about $843,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.